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Summary
Background: An enhanced efficacy of local as compared to 
systemic administration of interleukin-2 (1L-2) has been 
demonstrated in several experimental tumors. We previously 
reported that guinea pigs with palpable tumors and regional 
micromet as tases could be cured by intratumoral injections of 
polyethylene glycol-modified IL-2 (PEG-IL-2). In the pre­
sent study this treatment schedule was applied in a clinical 
situation.
Patients and methods: Nineteen patients with 11 local and 
11 regional recurrences of head and neck squamous cell car- 
cinoma (HNSCC) were treated with intratumoral injections 
of 200,000 U of PEGTL-2 3 times weekly in courses of 4 
weeks.
Results: Treatment was given on an out-patient basis> and 
was well tolerated. Temporary regional swelling and redness 
developed in 10 patients, and in 9 of them systemic eosino-
phiha was documented. Median duration of treatment was 4 
weeks (range 2-14 weeks), Seventeen patients were evalu­
able for response. One complete response (CR; 6%; duration 
91 weeks), and 6 stable diseases (SDs; duration 8-57+ 
weeks) were recorded. The CR and the 3 best SDs (23, 40, 
57+ weeks) occurred in patients with a single regional tumor 
recurrence of relatively small size. During treatment, all 4 
developed loco regional edema and redness, and high levels 
of circulating eosinophils. Median survival was 23 weeks for 
all patients, and 45+ weeks for the patients with SD,
Conclusion: Intratumoral injection of PEGTL-2 in pa­
tients with HNSCC is feasible. This treatment appears bene­
ficial for highly selected patients. The objective response rate 
is insufficient to justify wide clinical application.
Key words : head and neck squamous-cell carcinoma, immu­
notherapy, PEG-interleukin-2
Introduction showed temporary tumor-growth inhibition only [4],
Head and neck squamous cell carcinoma (HNSCC) 
The efficacy of locoregional injections with low doses appears to be a suitable disease in which to evaluate 
of interleukin-2 (IL-2) has been described in several local IL-2 immunotherapy in man. This tumor is local- 
experimental tumors. Besides locoregional antitumor izecl near the body surface, close to submucosal and 
effects, this approach has been shown to induce spe- nodular lymphatic tissue, and tends to recur loco­
regionally after primary therapy, Cortesina et al. [6, 7] 
obtained objective responses with perilymphatic IL-2
(i.e., around the tumor-draining lymph
cific systemic immunity, which resulted in rejection of 
tumor cells inoculated at distant sites |l~-3|, The peri- 
tumoral administration route of IL-2 and the presence
of lymphocytes at the tumor site appeared to be pre- nodes) in locoregionally recurrent HNSCC (6/10 and
requisites for these effects. It was hypothesized that 4/31 patients). We could not confirm this in patients
host immune cells at the tumor site were activated by with primary locoregionally far-advanced disease [8j.
exogenous IL-2 to produce cytokines and to recruit Partial responses were also described in HNSCC pa-
specific and nonspecific immune effector mechanisms dents using combined perilymphatic and intratumoral
, We analyzed locoregional immunotherapy in the IL-2 injections (2/36 patients) [9], intra-arterial IL-2
guinea pig line-10 tumor model |4j. In addition to IL-2, 
polyethylene glycol (PEG)-modificd IL-2 was also
infusion (2/12 pi 10], and combined locore­
gional IL-2 and LÀK cell administration (3/14 pa-
uscd, enhancing solubility and plasma half-life [5], tients) [11], The aim of the present study was to evalu-
It was found that guinea-pigs with palpable tumors ate the feasibility and the local antitumor effects of
on the flank and micrometastases in the regional intratumoral PEG-IL-2 injections in HNSCC, in a
lymph nodes could be cured by intratumoral, but not schedule which had been found to be optimal in our
perilymphatic, injections of PEG-IL-2, whereas IL-2 animal study [4],
958
Patients and methods
Nineteen patients ( 13 men, 6 women) with a median age of 69 years 
(range 46-83), gave informed consent and entered this study. Eli­
gible patients had to have measurable, histologically- or cytologi- 
cally-confirmed locoregional recurrence of HNSCC since previous 
surgery and/or radiotherapy at not more than two sites, for which 
no curative treatment was available. Tumor recurrences had to be 
accessible to injection, and could not exceed 8 cm at the largest 
diameter. Further eligibility criteria included: Karnofsky perfor­
mance status >70%, expected survival >3 months, normal hema­
tologic parameters, adequate hepatic, renal, and cardiac function, no 
other significant medical conditions requiring ongoing therapy, no 
organ allografts, no concurrent corticosteroid therapy, and no dis­
tant métastasés. The study was carried out with ethical committee 
approval.
Recombinant human IL-2 modified by the covalent attachment 
of 2-3 PEG Mr 7,000 molecules per IL~2 molecule (PEG-IL-2) was 
provided by EuroCetus, Amsterdam, The Netherlands. Specific 
activity was 85.7 x 105 (Lotno. LCP-920) or 40.0 x 105 (Lotno, 
LCP-039B) U/mg IL-2 protein. Intralesional injections with 
200,000 U PEG-IL-2 in 0.5 ml normal saline, containing 0.1% 
human serum albumin, were given 3 times a week for 4 weeks. 
Patients with 2 tumor recurrences received a double dose. Response 
to treatment was evaluated after 4 weeks, and defined according to 
WHO criteria. Patients with progressive disease (PD) were removed 
from the study, in instances of stable disease (SD) treatment was 
continued for 8 weeks. Objective responders were scheduled to 
receive 12 weeks of treatment without interruption. Response dura­
tion and patient survival were determined from the start of PEG- 
IL-2 treatment.
Results
In 19 patients 22 tumor recurrences were treated 
(Table 1). Prior treatment included radiotherapy (all 
19), primary tumor resection (14 patients), neck lymph 
node dissection (unilateral in 6 and bilateral in 5), and
chemotherapy (4 patients). Median time between con­
clusion of previous treatment and diagnosis of the cur­
rent tumor recurrence was 4 months. PEG-IL-2 was 
injected preferably in vital tumor borders, rather than 
in necrotic central parts. For treatment of lymph node 
métastasés the injection site and depth were deter­
mined by ultrasound. Seventeen patients were evalu­
able for response. One complete response (CR; 6%) 
was obtained in a man with a subcutaneous metastasis 
in the neck. Shrinkage of the lesion was first observed 
after 3 weeks of PEG-IL-2 treatment. After 8 weeks a 
flat skin lesion remained, which could no longer be 
injected. Treatment was then stopped, and 4 weeks 
later the lesion had disappeared completely (Fig. 1), 
The CR persisted for 91 weeks. The subsequent tumor 
recurrence was not accessible to injection. In 6 patients 
SD was recorded (duration 8-57+ weeks). Patients 
with progressive tumor growth at evaluation after 4 
weeks, or before completing the successive 4 weeks oi 
treatment were recorded as PD. Two patients were not 
evaluable for response, one because of unmeasurable 
disease, and the other because of early death. The lattei 
occurred in a 66-year~old man who unexpectedly died 
during his sleep about 36 hours after the 5th PEG-IL-2 
administration for 2 skin métastasés on the cheek 
Autopsy was not permitted and the cause of death re­
mained uncertain. A  relationship with PEG-IL-2 treat­
ment was considered unlikely. Chemotherapy, given tc
5 patients (Nos. 3, 4, 14, 16, and 17) for progressive 
tumor growth following PEG-IL-2 therapy, did no 
result in objective responses. Median survival from the 
start of PEG-IL-2 treatment was 23 weeks for the tota 
group, and 45+ weeks for the 6 patients who achievec 
SD.
Table J. HNSCC locoregional recurrences and inlratumoral PEG-IL-2 treatment.














1 subc. 7.2 8 CR (91 ) 102+ swelling, redness 1 140
2 l.n. (2) 3.1; 3.2 2 Early progression 9 swelling, redness 962
3 l.n. 4.3 8 SD (40) 59 swelling, redness, itching 2436
4 subc, 10,8 4 PD 20 none 320
5 prim. 3.8 6 PD 23 swelling, redness 720
6 prim. 12.0 6 PD 24 enhanced tumor necrosis 231
7 prim. 1.5 8 SD (8) 39 swelling, redness 726
8 l.n. + prim. 5.5; 5.3 8 SD (8) 22 swelling, redness, mild pain 710
9 prim, 36.0 2 Early progression 14 none 97
10 prim. 42.0 4 PD 8 none 186
11 prim. 4.9 4 PD 8 none 162
12 l.n. 1.6 4 SD (57+) 57+' swelling, redness, itching 3515
13 prim. not meas­
urable
I4d not measurable 31 swelling, redness 688
14 l.n. 20.0 8 SD (23) 52+ swelling, redness, itching 4653
15 prim, 6.3 4 PD 38+ none 70
16 l.n. 23.4 8 SD (12) 36+ mild pain 99
17 prim. 15.0 4 PD 11 none 152
18 skin (2) 3.6; 2.0 2 not evaluable 2 swelling, redness n.m.
19 prim. 6.0 4 PD 6 mild pain 260
1 su be.: subcutaneous; l.n.: lymph node; prim,; primary tumor site. h Product of largest bi perpendicular diameters. c Normal count <400 
lOVI. n.iru: not measured.1,1Therapy was continued for 14 weeks because of subjective improvement.
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patients with locoregionally recurrent disease after pre­
vious surgical and/or radiation therapy was low (6%). 
Nevertheless, the long-lasting CR indicates that a 
highly effective antitumor mechanism can be induced 
in certain circumstances. A  favorable response in 
patients with large or very fast-growing tumors appears 
unlikely. The patient with the CR and the 3 with SD of 
substantial duration all had a single regional tumor 
recurrence of relatively small size. During treatment 
these 4 patients developed high levels of circulating 
eosinophils and, along with 6 others, locoregional 
swelling and redness. Whether these observations are 
related to the tumor response remains speculative. In 
this study sufficient material could not be obtained for
ical analysis of PEG-IL-2-induced local
reactions. However, a local indurative and erythema­
tous reaction after subcutaneous IL-2 or PEG-IL-2 
injection in humans, resembling a delayed-type hyper­
sensitivity reaction and consisting of mononuclear cell 
infiltration, has been previously described [12]. In the 
line-10 guinea-pig tumor, in which we previously evalu­
ated intratumoral PEG-IL-2 therapy [4], an intense 
inflammatory reaction with eosinophils, T lympho­
cytes, macrophages and fibroblasts was observed at the 
site of regressing tumors (unpublished data). An as­
sociation between eosinophilia and a favorable tumor 
response has been described in patients receiving sub­
cutaneous IL-2 and IFNa therapy [13], Tepper et al, 
provided evidence for eosinophil-mediated tumor-cell 
killing in vivo [14].
In the present study, a single, intermediate dose-level 
for PEG-IL-2 was chosen. This dose was based on our 
experimental results with intratumoral PEG-IL-2 in the 
fast-growing guinea-pig line-10 turnon It is uncertain 
whether the present dose is optimal for HNSCC In 
previous studies with locoregional IL-2 administration 
in HNSCC, there were no indications that high IL-2 
doses yield better results [7, 9, 10]. in contrast, most 
objective clinical responses were obtained, especially 
All patients were evaluable for toxicity. Treatment with daily locoregional administration of relatively low 
was well tolerated. No systemic toxicity was observed, doses (200-30,000 U) of IL-2 [6,7,10],
Fig, I. Nodular subcutaneous tumor recurrence (30 x 24 mm, cyto- 
logically confirmed squamous cell carcinoma, with documented 
progressive growth) in the upper jugular region of the left neck, in a 
69-year-old man who was previously treated with radiotherapy, 
laryngectomy, and bilateral neck lymph node dissection for poorly- 
differentiated squamous cell carcinoma of the larynx, a, before 
PEG-IL-2 treatment, b, complete response, 4 weeks after stopping 
treatment with 3 times weekly 200,000 U PEG-IL-2 injections for 8
Swelling and redness of the neck and/or face on the We conclude that a minority of patients with loco-
side of injection developed in 10 patients. The swelling regionally recurrent HNSCC might benefit from intra
tumoral PEG-IL-2 injections, Therapy is well tolerated. 
The antitumor mechanism is unknown. M-»a£A
consisted of thickening of the skin and subcutaneous 
edema, as was confirmed by ultrasound examination.
This reaction generally started after 1 week of treat­
ment, and decreased from 1-2 weeks after cessation of 
treatment. Hematological blood counts revealed tem- this kind of locoregional immunotherapy. An alternati- 
porary eosinophilia during treatment in 9 patients, ve study design, with intratumoral PEG-IL-2 injections 
Interestingly, these were the same patients who devel- prior to tumor resection and regional lymph node dis-
knowledge about the underlying mechanism would 
make possible identification of patients susceptible to
oped locoregional swelling and redness (Table 1),
Discussion
section, appears appropriate. It could provide material 
for thorough histological and immunological analysis 
of PEGTL-2-induced locoregional reactions. More­
over, this patient group might be more susceptible to 
immunotherapy because their regional lymphatic sys-
Intratumoral injection of PEG-IL-2, 3 times weekly at tem has not been disturbed by previous surgery, 
intermediate doses, in patients with HNSCC appeared 
feasible. Treatment was given in the out-patient clinic, 
and toxicity was mild. The response rate obtained in
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